Treatment decisions are primarily driven by the tumor's biological profile, specifically Hormone Receptor (HR) and HER2 status. HR-Positive, HER2-Negative (Luminal)
For patients with ESR1 mutations , newer oral selective estrogen receptor degraders (SERDs) like elacestrant are increasingly utilized. HER2-Positive SENORIF 2025-2026 - Institut Curie Download Traitement cancer sein mГ©tastatique pdf
As of early 2026, the European Commission approved inavolisib (Itovebi) for use in combination with palbociclib and fulvestrant for advanced forms of the disease. Treatment decisions are primarily driven by the tumor's